• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
GTG 0.00% 3.9¢

GENETIC TECHNOLOGIES LIMITED - Announcements

Genetic Technologies Limited is an Australia-based diversified molecular diagnostics... Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and morMore

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk

Filters [Clear]
  • Price Sensitive: Yes
GTGAppendix 4C - quarterlyPRICE SENSITIVE28/10/10
GTGPreliminary Final ReportPRICE SENSITIVE30/08/10
GTGSettlement of disputePRICE SENSITIVE26/08/10
GTGGTG grants license to MonsantoPRICE SENSITIVE06/08/10
GTGAppendix 4C - quarterlyPRICE SENSITIVE28/07/10
GTGExtension of Quest LicensePRICE SENSITIVE29/06/10
GTGPatent claims upheld in full by USPTOPRICE SENSITIVE10/05/10
GTGGTG grants license to EraGen BiosciencesPRICE SENSITIVE05/05/10
GTGGTG grants non-coding license to Gen-ProbePRICE SENSITIVE03/05/10
GTGAppendix 4C - quarterlyPRICE SENSITIVE28/04/10
GTGAcquisition of BREVAGenPRICE SENSITIVE14/04/10
GTGAppendix 3BPRICE SENSITIVE14/04/10
GTGHalf Yearly Report and AccountsPRICE SENSITIVE25/02/10
GTGAppendix 4C - quarterlyPRICE SENSITIVE29/01/10
GTGResponse Genetics Distribution AgreementPRICE SENSITIVE06/01/10
GTGExclusive Option AgreementPRICE SENSITIVE17/12/09
GTGAppendix 4C - quarterlyPRICE SENSITIVE29/10/09
GTGRosetta Genomics Distribution AgreementPRICE SENSITIVE23/10/09
GTGPreliminary Final ReportPRICE SENSITIVE28/08/09
GTGAppendix 4C - quarterlyPRICE SENSITIVE30/07/09
GTGWithdrawal of German nullification actionPRICE SENSITIVE10/06/09
GTGImmunAid project updatePRICE SENSITIVE09/06/09
GTGAppendix 4C - quarterlyPRICE SENSITIVE29/04/09
GTGHalf Yearly Report and AccountsPRICE SENSITIVE26/02/09
GTGAppendix 4C - quarterlyPRICE SENSITIVE29/01/09
GTGGranting of licensePRICE SENSITIVE22/12/08
GTGResignation of DirectorPRICE SENSITIVE12/12/08
GTGTrading HaltPRICE SENSITIVE12/12/08
GTGNew position re BRCA testingPRICE SENSITIVE02/12/08
GTGAppendix 4C - quarterly
28/10/10PRICE SENSITIVE
GTGPreliminary Final Report
30/08/10PRICE SENSITIVE
GTGSettlement of dispute
26/08/10PRICE SENSITIVE
GTGGTG grants license to Monsanto
06/08/10PRICE SENSITIVE
GTGAppendix 4C - quarterly
28/07/10PRICE SENSITIVE
GTGExtension of Quest License
29/06/10PRICE SENSITIVE
GTGPatent claims upheld in full by USPTO
10/05/10PRICE SENSITIVE
GTGGTG grants license to EraGen Biosciences
05/05/10PRICE SENSITIVE
GTGGTG grants non-coding license to Gen-Probe
03/05/10PRICE SENSITIVE
GTGAppendix 4C - quarterly
28/04/10PRICE SENSITIVE
GTGAcquisition of BREVAGen
14/04/10PRICE SENSITIVE
GTGAppendix 3B
14/04/10PRICE SENSITIVE
GTGHalf Yearly Report and Accounts
25/02/10PRICE SENSITIVE
GTGAppendix 4C - quarterly
29/01/10PRICE SENSITIVE
GTGResponse Genetics Distribution Agreement
06/01/10PRICE SENSITIVE
GTGExclusive Option Agreement
17/12/09PRICE SENSITIVE
GTGAppendix 4C - quarterly
29/10/09PRICE SENSITIVE
GTGRosetta Genomics Distribution Agreement
23/10/09PRICE SENSITIVE
GTGPreliminary Final Report
28/08/09PRICE SENSITIVE
GTGAppendix 4C - quarterly
30/07/09PRICE SENSITIVE
GTGWithdrawal of German nullification action
10/06/09PRICE SENSITIVE
GTGImmunAid project update
09/06/09PRICE SENSITIVE
GTGAppendix 4C - quarterly
29/04/09PRICE SENSITIVE
GTGHalf Yearly Report and Accounts
26/02/09PRICE SENSITIVE
GTGAppendix 4C - quarterly
29/01/09PRICE SENSITIVE
GTGGranting of license
22/12/08PRICE SENSITIVE
GTGResignation of Director
12/12/08PRICE SENSITIVE
GTGTrading Halt
12/12/08PRICE SENSITIVE
GTGNew position re BRCA testing
02/12/08PRICE SENSITIVE
(20min delay)
Last
3.9¢
Change
0.000(0.00%)
Mkt cap ! $5.671M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0
GTG (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.